Claude Opus commit added malicious npm dependency in Feb 2026, enabling crypto theft and persistent RAT access.
Excel has quietly gained dynamic arrays, XLOOKUP, Power Query, and Python, yet many still work the old way.
XDA Developers on MSN
Claude Code replaced my bloated PC optimization tools with custom scripts, and my Windows PC has never been happier
Say "no" to running dubious scripts.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...
Neuronal specification, expansion and differentiation are tightly regulated by the concerted actions of transcription and chromatin modifying factors that are recruited to regulatory elements in the ...
2-Year U.S. Treasury Note Continuous Contract $103.645-0.078-0.08% 5-Year U.S. Treasury Note Continuous Contract $107.984-0.188-0.17% 10-Year U.S. Treasury Note Continuous Contract $110.781-0.250-0.23 ...
Wall-to-wall foreign stock exposure. Our research team assigns Gold ratings to strategies that they have the most conviction will outperform a relevant index, or most peers, over a market cycle on a ...
There is no recent news for this security. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to your inbox Get this delivered to your ...
U.S. to Ask States to Revalidate "high-risk" Medicaid Providers Mehmet Oz, who heads the agency that runs the U.S. Medicare and Medicaid healthcare programs, said on Tuesday the Trump administration ...
Cheap US large-cap value exposure. Our research team assigns Gold ratings to strategies that they have the most conviction will outperform a relevant index, or most peers, over a market cycle on a ...
The Schwab S&P 500 Index tracks the Standard & Poor's 500 index, one of the most widely watched benchmarks for U.S. stocks. The index covers about 80 percent of the investable market capitalization of ...
AACR 2026 Daraxonrasib Combo Shows Promise in First-Line mPDAC A phase 1/2 trial shows strong early efficacy for daraxonrasib plus chemotherapy as first-line treatment for patients with metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results